Matt joined NEA in 2018 and is currently a Partner on the healthcare team. He focuses on biopharma investments.
Prior to NEA, Matt was a Principal at F-Prime Capital Partners. During his five years at F-Prime, he was responsible for closing investments in more than 20 private biopharma companies, and served on the board of more than 10 portfolio companies. Prior to F-Prime, he was a management consultant in the health and life sciences practice at Oliver Wyman, a biotech equity research analyst at Robert W. Baird, and a healthcare investment banker at JP Morgan. He also conducted lipid metabolism research at the National Institute of Diabetes, Digestive and Kidney Disorders. Matt is a board member of AviadoBio, Escient Pharma, and Recludix Pharma.
Matt received a BA with Honors in Biological Sciences from the University of Chicago, an MD from the University of Illinois, and an MBA from the University of Chicago Booth School of Business.